Evidence map›Paper›PMID 31011919›Full record

ArticleJournal of molecular histology2019

Rilpivirine as a potential candidate for the treatment of HIV-associated neurocognitive disorders (HAND).

Sphamandla Ntshangase, Sipho Mdanda, Tricia Naicker, Hendrik G Kruger, Thavendran Govender, Sooraj Baijnath

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of molecular histology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.9field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Sphamandla NtshangaseCatalysis and Peptide Research Unit, University of KwaZulu-Natal, Westville Campus, E-block, 6th floor, Room E1-06-016, Durban, South Africa.
Sipho MdandaCatalysis and Peptide Research Unit, University of KwaZulu-Natal, Westville Campus, E-block, 6th floor, Room E1-06-016, Durban, South Africa.
Tricia NaickerCatalysis and Peptide Research Unit, University of KwaZulu-Natal, Westville Campus, E-block, 6th floor, Room E1-06-016, Durban, South Africa.
Hendrik G KrugerCatalysis and Peptide Research Unit, University of KwaZulu-Natal, Westville Campus, E-block, 6th floor, Room E1-06-016, Durban, South Africa.
Thavendran GovenderCatalysis and Peptide Research Unit, University of KwaZulu-Natal, Westville Campus, E-block, 6th floor, Room E1-06-016, Durban, South Africa.
Sooraj BaijnathCatalysis and Peptide Research Unit, University of KwaZulu-Natal, Westville Campus, E-block, 6th floor, Room E1-06-016, Durban, South Africa. baijnath.sooraj@gmail.com.ORCID http://orcid.org/0000-0001-7860-1779
University of KwaZulu-Natal · ZA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

As the HIV epidemic continues to contribute to global morbidity and mortality, the prevalence of HIV-associated neurological disorders (HAND) also continues to be a major concern in infected individuals, despite the widespread use of combination antiretroviral therapy. Therefore, current antiretroviral drugs should be able to reach therapeutic levels in the brain for the treatment of HAND. The brain distribution of the next-generation non-nucleoside reverse transcriptase inhibitor, rilpivirine (RPV) was investigated in healthy female Sprague-Dawley (SD) rats. The presented study involves the use of liquid chromatography-tandem mass spectrometry (LC-MS/MS) to estimate the concentrations of RPV in plasma and brain homogenate samples. The use of matrix-assisted laser desorption/ionization mass spectrometry imaging (MALDI-MSI) provided regional spatial distribution of RPV in brain tissue sections. The localization of RPV was found to be relatively high in the hypothalamus, thalamus and corpus callosum, brain regions known to be associated with neurodegeneration during HAND (including the cerebral cortex). This study has shown that RPV has an excellent blood-brain barrier penetrability. Thus, in combination with other antiretroviral drugs, better central nervous system (CNS) protection against HAND can possibly be achieved.

Indexed as

AnimalsBlood-Brain BarrierBrainChromatography, LiquidFemaleHIV InfectionsHumansNeurocognitive DisordersRatsRats, Sprague-DawleyReverse Transcriptase InhibitorsRilpivirineTandem Mass SpectrometryReverse Transcriptase InhibitorsRilpivirineCentral nervous systemDrug distributionMass spectrometry imagingRilpivirine

Identifiers

PMID31011919
OpenAlexW2942085536

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.